Detection of glioblastoma in biofluids
The detection of glioblastoma (GBM) in biofluids offers potential advantages over existing paradigms for the diagnosis and therapeutic monitoring of glial tumors. Biofluid-based detection of GBM focuses on detecting tumor-specific biomarkers in the blood and CSF. Current clinical research concentrat...
Gespeichert in:
| Veröffentlicht in: | Journal of neurosurgery 2018-08, Vol.129 (2), p.334-340 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 340 |
|---|---|
| container_issue | 2 |
| container_start_page | 334 |
| container_title | Journal of neurosurgery |
| container_volume | 129 |
| creator | Figueroa, Javier M Carter, Bob S |
| description | The detection of glioblastoma (GBM) in biofluids offers potential advantages over existing paradigms for the diagnosis and therapeutic monitoring of glial tumors. Biofluid-based detection of GBM focuses on detecting tumor-specific biomarkers in the blood and CSF. Current clinical research concentrates on studying 3 distinct tumor-related elements: extracellular macromolecules, extracellular vesicles, and circulating tumor cells. Investigations into these 3 biological classifications span the range of locales for tumor-specific biomarker discovery, and combined, have the potential to significantly impact GBM diagnosis, monitoring for treatment response, and surveillance for recurrence. This review highlights the recent advancements in the development of biomarkers and their efficacy for the detection of GBM. |
| doi_str_mv | 10.3171/2017.3.JNS162280 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1954069905</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1954069905</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-635c122619f69ccd9c5ddcc11483c93cfded6031d77ea6cd8d780990be885ed93</originalsourceid><addsrcrecordid>eNo9kD1PwzAURS0EoqWwM6FMiCXlPb_GsUfU8qkKBmC2EttBRkld4mTg35OopdNd7j26OoxdIswJc7zlgPmc5i-v7yg4l3DEpqiIUhCKjtkUgPOUQGYTdhbjNwCKheCnbMIVZDSUpux65TpnOh82SaiSr9qHsi5iF5oi8Zuk9KGqe2_jOTupijq6i33O2OfD_cfyKV2_PT4v79apISm7VFBmkHOBqhLKGKtMZq0xiAtJRpGprLMCCG2eu0IYK20uQSkonZSZs4pm7GbH3bbhp3ex042PxtV1sXGhjxpVthh-j_dnDHZV04YYW1fpbeubov3VCHq0o0c7mvTBzjC52tP7snH2MPjXQX_d916v</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1954069905</pqid></control><display><type>article</type><title>Detection of glioblastoma in biofluids</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Figueroa, Javier M ; Carter, Bob S</creator><creatorcontrib>Figueroa, Javier M ; Carter, Bob S</creatorcontrib><description>The detection of glioblastoma (GBM) in biofluids offers potential advantages over existing paradigms for the diagnosis and therapeutic monitoring of glial tumors. Biofluid-based detection of GBM focuses on detecting tumor-specific biomarkers in the blood and CSF. Current clinical research concentrates on studying 3 distinct tumor-related elements: extracellular macromolecules, extracellular vesicles, and circulating tumor cells. Investigations into these 3 biological classifications span the range of locales for tumor-specific biomarker discovery, and combined, have the potential to significantly impact GBM diagnosis, monitoring for treatment response, and surveillance for recurrence. This review highlights the recent advancements in the development of biomarkers and their efficacy for the detection of GBM.</description><identifier>ISSN: 0022-3085</identifier><identifier>EISSN: 1933-0693</identifier><identifier>DOI: 10.3171/2017.3.JNS162280</identifier><identifier>PMID: 29053069</identifier><language>eng</language><publisher>United States</publisher><ispartof>Journal of neurosurgery, 2018-08, Vol.129 (2), p.334-340</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c388t-635c122619f69ccd9c5ddcc11483c93cfded6031d77ea6cd8d780990be885ed93</citedby><cites>FETCH-LOGICAL-c388t-635c122619f69ccd9c5ddcc11483c93cfded6031d77ea6cd8d780990be885ed93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29053069$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Figueroa, Javier M</creatorcontrib><creatorcontrib>Carter, Bob S</creatorcontrib><title>Detection of glioblastoma in biofluids</title><title>Journal of neurosurgery</title><addtitle>J Neurosurg</addtitle><description>The detection of glioblastoma (GBM) in biofluids offers potential advantages over existing paradigms for the diagnosis and therapeutic monitoring of glial tumors. Biofluid-based detection of GBM focuses on detecting tumor-specific biomarkers in the blood and CSF. Current clinical research concentrates on studying 3 distinct tumor-related elements: extracellular macromolecules, extracellular vesicles, and circulating tumor cells. Investigations into these 3 biological classifications span the range of locales for tumor-specific biomarker discovery, and combined, have the potential to significantly impact GBM diagnosis, monitoring for treatment response, and surveillance for recurrence. This review highlights the recent advancements in the development of biomarkers and their efficacy for the detection of GBM.</description><issn>0022-3085</issn><issn>1933-0693</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNo9kD1PwzAURS0EoqWwM6FMiCXlPb_GsUfU8qkKBmC2EttBRkld4mTg35OopdNd7j26OoxdIswJc7zlgPmc5i-v7yg4l3DEpqiIUhCKjtkUgPOUQGYTdhbjNwCKheCnbMIVZDSUpux65TpnOh82SaiSr9qHsi5iF5oi8Zuk9KGqe2_jOTupijq6i33O2OfD_cfyKV2_PT4v79apISm7VFBmkHOBqhLKGKtMZq0xiAtJRpGprLMCCG2eu0IYK20uQSkonZSZs4pm7GbH3bbhp3ex042PxtV1sXGhjxpVthh-j_dnDHZV04YYW1fpbeubov3VCHq0o0c7mvTBzjC52tP7snH2MPjXQX_d916v</recordid><startdate>201808</startdate><enddate>201808</enddate><creator>Figueroa, Javier M</creator><creator>Carter, Bob S</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201808</creationdate><title>Detection of glioblastoma in biofluids</title><author>Figueroa, Javier M ; Carter, Bob S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-635c122619f69ccd9c5ddcc11483c93cfded6031d77ea6cd8d780990be885ed93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Figueroa, Javier M</creatorcontrib><creatorcontrib>Carter, Bob S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neurosurgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Figueroa, Javier M</au><au>Carter, Bob S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Detection of glioblastoma in biofluids</atitle><jtitle>Journal of neurosurgery</jtitle><addtitle>J Neurosurg</addtitle><date>2018-08</date><risdate>2018</risdate><volume>129</volume><issue>2</issue><spage>334</spage><epage>340</epage><pages>334-340</pages><issn>0022-3085</issn><eissn>1933-0693</eissn><abstract>The detection of glioblastoma (GBM) in biofluids offers potential advantages over existing paradigms for the diagnosis and therapeutic monitoring of glial tumors. Biofluid-based detection of GBM focuses on detecting tumor-specific biomarkers in the blood and CSF. Current clinical research concentrates on studying 3 distinct tumor-related elements: extracellular macromolecules, extracellular vesicles, and circulating tumor cells. Investigations into these 3 biological classifications span the range of locales for tumor-specific biomarker discovery, and combined, have the potential to significantly impact GBM diagnosis, monitoring for treatment response, and surveillance for recurrence. This review highlights the recent advancements in the development of biomarkers and their efficacy for the detection of GBM.</abstract><cop>United States</cop><pmid>29053069</pmid><doi>10.3171/2017.3.JNS162280</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3085 |
| ispartof | Journal of neurosurgery, 2018-08, Vol.129 (2), p.334-340 |
| issn | 0022-3085 1933-0693 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1954069905 |
| source | EZB-FREE-00999 freely available EZB journals |
| title | Detection of glioblastoma in biofluids |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A46%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Detection%20of%20glioblastoma%20in%20biofluids&rft.jtitle=Journal%20of%20neurosurgery&rft.au=Figueroa,%20Javier%20M&rft.date=2018-08&rft.volume=129&rft.issue=2&rft.spage=334&rft.epage=340&rft.pages=334-340&rft.issn=0022-3085&rft.eissn=1933-0693&rft_id=info:doi/10.3171/2017.3.JNS162280&rft_dat=%3Cproquest_cross%3E1954069905%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1954069905&rft_id=info:pmid/29053069&rfr_iscdi=true |